Compare Stocks

→ Could Your Accounts Be Frozen? (From Allegiance Gold) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACUS Acusphere		$0.00	$0.00 ▼ $0.05	N/A	-1.31	1 shs	125 shs
AFFY Affymax	$0.00	$0.00	$0.00 ▼ $0.04	N/A	6.01	26,181 shs	N/A
ALSE Alseres Pharmaceuticals	$0.01	$0.01	$0.01 ▼ $0.01	N/A	0.13	N/A	N/A
MYNZ Mainz Biomed	$0.74 -3.9%	$0.97	$0.72 ▼ $6.00	N/A	0.28	102,130 shs	169,563 shs
TSVT 2seventy bio	$4.76 -3.4%	$4.95	$1.53 ▼ $12.69	$244.66M	1.87	1.34 million shs	598,331 shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACUS Acusphere	0.00%	0.00%	0.00%	0.00%	0.00%
AFFY Affymax	0.00%	0.00%	0.00%	-66.67%	-82.93%
ALSE Alseres Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-50.00%
MYNZ Mainz Biomed	-0.64%	-10.70%	-31.69%	-12.56%	-86.01%
TSVT 2seventy bio	+7.17%	+14.92%	-0.20%	-6.10%	-50.95%

Biden replacement revealed? (Ad)

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACUS Acusphere	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AFFY Affymax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ALSE Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MYNZ Mainz Biomed	1.5023 of 5 stars	3.3	4.0	0.0	0.0	1.8	0.8	0.0
TSVT 2seventy bio	2.7336 of 5 stars	3.2	2.0	0.0	0.0	2.5	3.3	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACUS Acusphere	N/A	N/A	N/A	N/A
AFFY Affymax	N/A	N/A	N/A	N/A
ALSE Alseres Pharmaceuticals	N/A	N/A	N/A	N/A
MYNZ Mainz Biomed	2.50	Moderate Buy	$6.00	714.44% Upside
TSVT 2seventy bio	2.38	Hold	$13.17	176.61% Upside

Current Analyst Ratings

Latest MYNZ, TSVT, ACUS, AFFY, and ALSE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/12/2024	MYNZ Mainz Biomed	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
4/8/2024	TSVT 2seventy bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $12.00
3/18/2024	TSVT 2seventy bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$5.00
3/6/2024	MYNZ Mainz Biomed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00

(Data available from 5/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACUS Acusphere	N/A	N/A	N/A	N/A	N/A	N/A
AFFY Affymax	N/A	N/A	N/A	N/A	N/A	N/A
ALSE Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
MYNZ Mainz Biomed	$900K	N/A	N/A	N/A	$0.27 per share	N/A
TSVT 2seventy bio	$100.39M	2.44	N/A	N/A	$5.04 per share	0.94

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACUS Acusphere	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
AFFY Affymax	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ALSE Alseres Pharmaceuticals	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MYNZ Mainz Biomed	-$26.30M	-$1.64	N/A	∞	N/A	-2,934.82%	-488.05%	-145.77%	5/21/2024 (Estimated)
TSVT 2seventy bio	-$217.57M	-$4.42	N/A	68.00	N/A	-216.73%	-59.19%	-29.67%	N/A

Latest MYNZ, TSVT, ACUS, AFFY, and ALSE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/9/2024	Q4 2023	MYNZ Mainz Biomed	N/A	-$0.24	-$0.24	-$0.24	N/A	$0.22 million
3/5/2024	12/31/2023	TSVT 2seventy bio	-$1.22	-$1.11	+$0.11	-$1.11	$13.91 million	$10.68 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACUS Acusphere	N/A	N/A	N/A	N/A	N/A
AFFY Affymax	N/A	N/A	N/A	N/A	N/A
ALSE Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MYNZ Mainz Biomed	N/A	N/A	N/A	N/A	N/A
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACUS Acusphere	N/A	N/A	N/A
AFFY Affymax	N/A	N/A	N/A
ALSE Alseres Pharmaceuticals	N/A	N/A	N/A
MYNZ Mainz Biomed	0.36	0.97	0.91
TSVT 2seventy bio	N/A	3.98	3.98

Ownership

Institutional Ownership

Company	Institutional Ownership
ACUS Acusphere	N/A
AFFY Affymax	N/A
ALSE Alseres Pharmaceuticals	N/A
MYNZ Mainz Biomed	N/A
TSVT 2seventy bio	93.90%

Insider Ownership

Company	Insider Ownership
ACUS Acusphere	4.60%
AFFY Affymax	1.55%
ALSE Alseres Pharmaceuticals	8.94%
MYNZ Mainz Biomed	18.20%
TSVT 2seventy bio	2.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ACUS Acusphere	118	N/A	N/A	Not Optionable
AFFY Affymax	2	N/A	N/A	Not Optionable
ALSE Alseres Pharmaceuticals	3	N/A	N/A	Not Optionable
MYNZ Mainz Biomed	65	N/A	N/A	Not Optionable
TSVT 2seventy bio	274	51.40 million	50.07 million	Optionable

MYNZ, TSVT, ACUS, AFFY, and ALSE Headlines

Source	Headline
	2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024 finance.yahoo.com - May 3 at 7:11 AM
	2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024 businesswire.com - May 3 at 7:00 AM
	2seventy bio, Inc. (NASDAQ:TSVT) Receives Consensus Recommendation of "Hold" from Analysts americanbankingnews.com - April 29 at 2:20 AM
	2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? zacks.com - April 24 at 11:07 AM
	2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why msn.com - April 17 at 1:11 PM
	2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why zacks.com - April 17 at 12:05 PM
	2seventy bio Inc Ordinary Shares morningstar.com - April 13 at 9:15 AM
	Citi raises 2Seventy Bio stock target on FDA approval investing.com - April 10 at 11:37 PM
	Analysts Offer Predictions for 2seventy bio, Inc.'s Q1 2024 Earnings (NASDAQ:TSVT) marketbeat.com - April 10 at 8:12 AM
	Leerink Partnrs Analysts Raise Earnings Estimates for 2seventy bio, Inc. (NASDAQ:TSVT) marketbeat.com - April 9 at 6:25 AM
	Positive Outlook for 2seventy bio’s ABECMA: Buy Rating Affirmed Amidst Expansion and Competitive Dynamics markets.businessinsider.com - April 8 at 7:36 PM
	2seventy bio (NASDAQ:TSVT) Price Target Raised to $12.00 marketbeat.com - April 8 at 7:29 PM
	Buy Rating and High Risk for 2seventy bio: FDA Approval and Market Expansion Fuel Optimistic Outlook markets.businessinsider.com - April 7 at 7:49 PM
	Bristol Myers Wins FDA Nod for Abecma msn.com - April 5 at 4:27 PM
	FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer msn.com - April 5 at 4:27 PM
	Bristol Myers, 2seventy bio's Abecma approved for earlier line multiple myeloma seekingalpha.com - April 5 at 4:27 PM
$U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy$	U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy finance.yahoo.com - April 5 at 9:35 AM
	2seventy bio, Inc. (NASDAQ:TSVT) Receives Consensus Recommendation of "Hold" from Brokerages marketbeat.com - April 4 at 2:15 AM
	Insider Buying: 2seventy bio, Inc. (NASDAQ:TSVT) Director Buys 300,000 Shares of Stock insidertrades.com - March 26 at 4:18 AM
	2seventy bio appoints Eli Casdin and Charles Newton to its board of directors msn.com - March 20 at 6:07 PM
	2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors businesswire.com - March 20 at 5:04 PM
	Thinking about buying stock in 2Seventy Bio, Verb Technology, Exscientia, MicroCloud Hologram, or Akebia Therapeutics? morningstar.com - March 20 at 1:07 PM
	Contineum Therapeutics files for IPO statnews.com - March 18 at 10:13 AM
	Bristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee Approval marketwatch.com - March 17 at 10:41 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acusphere

OTCMKTS:ACUS

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.

Affymax

OTCMKTS:AFFY

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Alseres Pharmaceuticals

OTCMKTS:ALSE

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

Mainz Biomed

NASDAQ:MYNZ

Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases. The company was founded in 2008 and is based in Mainz, Germany.

2seventy bio

NASDAQ:TSVT

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial